We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 23, 2020

FGFR3 Status Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Urothelial Carcinoma

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Fibroblast Growth Factor Receptor 3 Alteration Status Is Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma
Eur Urol 2020 Dec 01;78(6)907-915, MY Teo, JM Mota, KA Whiting, HA Li, SA Funt, CH Lee, DB Solit, H Al-Ahmadie, MI Milowsky, AV Balar, E Pietzak, G Dalbagni, BH Bochner, I Ostrovnaya, DF Bajorin, JE Rosenberg, G Iyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading